Interspecies scaling of bosentan, a new endothelin receptor antagonist and integration of in vitro data into allometric scaling

Pharmaceutical Research

Volumn 13, Issue 1, 1996, Pages 97-101

  Lave, Thierry ^a   Coassolo, Philippe ^a   Ubeaud, Geneviève ^a   Brandt, Roger ^a   Schmitt, Christophe ^a   Dupin, Sylvie ^a   Jaeck, Daniel ^b   Chou, Ruby C ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Allometric scaling; Bosentan; Clearance; In vitro models; Interspecies scaling; Pharmacokinetics

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST;

ALLOMETRY; ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME; MALE; MARMOSET; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RABBIT; RAT;

ANIMALS; CALLITHRIX; DOGS; HUMANS; LINEAR MODELS; METABOLIC CLEARANCE RATE; MICE; MODELS, BIOLOGICAL; RABBITS; RATS; RECEPTORS, ENDOTHELIN; SPECIES SPECIFICITY; SULFONAMIDES;

EID: 0029912492     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016037519116     Document Type: Article

References (15)

1. Y. Sawada, M. Hanano, Y. Sugiyama, and T. Iga . Prediction of the disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals. J. Pharmacokinet. Biopharm. 12:241-61 (1984).
2. B. Boxenbaum, and R. W. D'Souza. Interspecies Pharmacokinetic Scaling, Biological Design and Neoteny. In B. Testa (eds.), Advances in Drug Research, Academic Press Limited, London, 1990, pp. 139-196.
3. P. J. McNamara. Interspecies scaling in pharmacokinetics. In P. G. Welling, F. L. S. Tse and S. V. Dighe (eds.), Pharmaceutical bioequivalence. Marcel Dekker, New York, 1991, pp. 267-300.
4. D. B. Campbell. Can allometric interspecies scaling be used to predict human kinetics. Drug Inf. J. 28:235-245 (1994).
5. H. Boxenbaum, and J. B. Fertig . Scaling of antipyrine intrinsic clearance of unbound drug in 15 mammalian species. Eur. J. Drug Metab. Pharmacokinet. 9:177-83 (1984).
6. T. Lave, A. H. Schmitt-Hoffmann, P. Coassolo, G. Ubeaud, B. Vallès, B. Ba, R. Brandt, and R. C. Chou . A new extrapolation method from animal to man ; application to a metabolized compound, mofarotene. Life Sci. 56:473-478 (1995).
7. C. Von Bahr, C.-G. Groth, H. Jansson, G. Lundgren, M. Lind, and H. Glaumann . Drug metabolism in human liver in vitro : Establishment of a human liver bank. Clin. Pharm. Ther. 27:711-725 (1980).
8. P. O. Seglen . Preparation of isolated rat liver cells. Meth. Cell Biol. 13:29-83 (1976).
9. T. Seddon, I. Michelle, and R. J. Chenery . Comparative drug metabolism of diazepam in hepatocytes isolated from man, rat, monkey and dog. Biochem. Pharmacol. 38:1657-1665 (1989).
10. J. Mordenti . Man versus beast: pharmacokinetic scaling in mammals. J. Pharm. Sci. 75:1028-40 (1986).
11. J. B. Houston . Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47:1469-1479 (1994).
12. K. S. Pang, P. Kong, J. A. Terrell, and R. E. Billings . Metabolism of acetaminophen and phenacetin by isolated rat hepatocytes. A system in which the spatial organization inherent in the liver is disrupted. Drug Metab. Dispos. 13:42-50 (1985).
13. A. Rane, G. R. Wilkinson, and D. G. Shand . Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J. Pharmacol. Exp. Ther. 200:420-4 (1977).
14. B. A. Hoener . Predicting the hepatic clearance of xenobiotics in humans from in vitro data. Biopharm. Drug Dispos. 15:295-304 (1994).
15. C. Bäärnhielm, H. Dählback, and I. Skanberg . In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. Acta Pharm. Toxicol. 59:113-22 (1986).